At RVL Pharmaceuticals, we strive to improve patients’ lives by providing innovative, clinically proven products that can help reshape how we approach ocular health.
Our current focus is delivering new products, such as Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, to address a significant unmet need among patients.
We invite you to review the Upneeq website and full Prescribing Information for more information. You can also review our products in development in our RVL Pipeline section below.